Elsevier

Clinics in Chest Medicine

Volume 31, Issue 3, September 2010, Pages 547-554
Clinics in Chest Medicine

Pulmonary Manifestations of Ankylosing Spondylitis

https://doi.org/10.1016/j.ccm.2010.05.002Get rights and content

Section snippets

Demographic features

Ankylosing spondylitis is estimated to affect 0.1% of the general population.8 However, there is significant variability in prevalence, ranging from approximately 2 per 1000 individuals among black South Africans to 63 per 1000 individuals among Canadian Bella Bella Indians.9 A strong familial pattern has been described with an estimated 10% increased likelihood of the disease identified among first-degree relatives of an affected individual.3

The disorder affects men more commonly than women.

Pathophysiology

Ankylosing spondylitis has been described in persons with amyloidosis, psoriasis, regional enteritis, systemic sclerosis, ulcerative colitis, and urogenital infections. These associations suggest that an inflammatory or immunologic process is responsible for its pathogenesis.2 It has been proposed that cross reactivity between microbial elements and specific histocompatibility antigens may trigger an altered immune reaction. Klebsiella-related antigens have been identified in persons with

Clinical features

Inflammation of the sacroiliac joints is an early manifestation, and patients may present with back pain or morning stiffness. Other joints of the axial skeleton and extremities may eventually be affected also. About 30% of the patients have peripheral joint involvement.3 Pain on inspiration secondary to limited chest wall expansion and straightening of the lumbar spine can occur.2

Ankylosing spondylitis can affect the ocular, cardiovascular, renal, and neurologic systems (Box 1).

Respiratory manifestations

The presence of pleuropulmonary disease in patients with ankylosing spondylitis was first described by Dunham and Kautz15 in 1941 and by Hamilton16 in 1949. Pulmonary involvement in ankylosing spondylitis consists most frequently of abnormalities of the thoracic cage and lung parenchyma.5, 6 In one study, pleuropulmonary involvement was observed in 28 (1.3%) of 2080 patients with ankylosing spondylitis,17 including 25 cases of apical fibrobullous changes, 2 of pleural effusions, and 1 of apical

Clinical course

Onset of symptoms is usually insidious and generally starts between 19 and 40 years of age.2 The disorder is characterized by progressive loss of functional capacity, with most of the impairment occurring in the first decade of the disease.42 Gran and Skomsvoll42 conducted a long-term study of 100 patients with this disorder, more than half of whom remained employed in full-time work after a mean disease duration of 16 years. The presence of “bamboo spine,” acute anterior uveitis, and

Evaluation

Many inflammatory and connective tissue diseases share features in common with ankylosing spondylitis, and laboratory tests may be required to help distinguish them. Patients with ankylosing spondylitis may demonstrate B-lymphocyte reactivity, circulating immune complexes, elevated levels of immunoglobulins, and increased serum levels of alkaline phosphatase and creatine phosphokinase.45 Bronchoalveolar lavage may be normal and may show no evidence of alveolitis or may reveal increased levels

Therapy of ankylosing spondylitis

No treatment has been shown to alter the clinical course of apical fibrobullous disease.1, 2, 3, 49 Therapy with antiinflammatory agents, such as phenylbutazone or diflunisal, for arthritic symptoms does not improve pulmonary function or halt the progression of the disease. Management of respiratory complications of ankylosing spondylitis is mainly related to treating pulmonary superinfections using antifungal or antibacterial agents, which are either administered systemically or instilled

Summary

Several pulmonary disorders have been described in patients with ankylosing spondylitis, and these can be associated with significant morbidity and mortality. Management is mainly aimed at treating pulmonary superinfections. New antiinflammatory agents for arthritic symptoms seem to have no significant effect on the natural course of pulmonary disorders in these patients.

First page preview

First page preview
Click to open first page preview

References (68)

  • D.W. Bulwark et al.

    Pulmonary manifestations of rheumatic diseases

    Clin Rev Allergy

    (1985)
  • S.M. Gupta et al.

    Apical pulmonary disease in ankylosing spondylitis

    N Z Med J

    (1978)
  • G.W. Hunninghake et al.

    Pulmonary involvement in the collagen vascular diseases

    Am Rev Respir Dis

    (1979)
  • L.T. Tanoue

    Pulmonary involvement in collagen vascular disease: a review of the pulmonary manifestations of the Marfan syndrome, ankylosing spondylitis, Sjogren's syndrome and relapsing polychondritis

    J Thorac Imaging

    (1992)
  • A.H. Wolson et al.

    Upper lobe fibrosis in ankylosing spondylitis

    Am J Roentgenol Radium Ther Nucl Med

    (1975)
  • A. Calin et al.

    Striking prevalence of ankylosing spondylitis in “healthy” W27 positive males and females

    N Engl J Med

    (1975)
  • S.S. Hurwitz et al.

    Fibrocavitating pulmonary lesions in ankylosing spondylitis

    S Afr Med J

    (1982)
  • S. Prakash et al.

    Ankylosing spondylitis in North India: a clinical and immunogenetic study

    Ann Rheum Dis

    (1984)
  • A.D. Beaulieu et al.

    Klebsiella related antigens in ankylosing spondylitis

    J Rheumatol

    (1983)
  • B. Blumberg et al.

    The natural history of rheumatoid spondylitis

    Medicine

    (1956)
  • D. Appelrouth et al.

    Pulmonary manifestations of ankylosing spondylitis

    J Rheumatol

    (1975)
  • C.L. Dunham et al.

    Spondylarthritis ankylopoietica. A review and report of twenty cases

    Am J Med Sci

    (1941)
  • K.A. Hamilton

    Pulmonary disease manifestations of ankylosing spondylarthritis

    Ann Intern Med

    (1949)
  • E. Rosenow et al.

    Pleuropulmonary manifestations of ankylosing spondylitis

    Mayo Clin Proc

    (1977)
  • J.R. Sinclair et al.

    Ankylosing spondylitis. The case for awake intubation

    Anaesthesia

    (1984)
  • P.S. Shankar

    Ankylosing spondylitis with fibrosis and carcinoma of the lung

    CA Cancer J Clin

    (1982)
  • B. Fournie et al.

    Prospective study of anterior chest wall involvement in ankylosing spondylitis and psoriatic arthritis

    Rev Rhum Engl Ed

    (1997)
  • E. Kentala et al.

    HLA-antigens and pulmonary upper lobe fibrocystic changes with and without ankylosing spondylitis

    Scand J Respir Dis

    (1978)
  • G. Hillerdal

    Ankylosing spondylitis lung disease—an underdiagnosed entity?

    Eur J Respir Dis

    (1983)
  • U.K. Repo et al.

    Pulmonary apical fibrocystic disease

    Eur J Respir Dis

    (1981)
  • M. Ferdoutis et al.

    Diffuse interstitial lung disease as an early manifestation of ankylosing spondylitis

    Respiration

    (1995)
  • R.M. Stewart et al.

    Regional lung function in ankylosing spondylitis

    Thorax

    (1976)
  • A.G. Jessamine

    Upper lobe fibrosis in ankylosing spondylitis

    Can Med Assoc J

    (1968)
  • B.A. Scobie

    Disturbed oesophageal manometric responses in patients with ankylosing spondylitis and pulmonary aspergilloma

    Australas Ann Med

    (1970)
  • Cited by (0)

    View full text